文献速递青光眼

抑制单核细胞趋化蛋白1可预防青光眼滤过手术实验模型中的结膜纤维化

Inhibition of Monocyte Chemoattractant Protein 1 Prevents Conjunctival Fibrosis in an Experimental Model of Glaucoma Filtration Surgery.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

在小鼠青光眼滤过手术模型中,比较单核细胞趋化蛋白1受体抑制剂(MCP-Ri)、丝裂霉素C(MMC)与溶媒对滤过泡存活和纤维化的影响。MCP-Ri较MMC或对照更降低结膜滤过泡中F4/80阳性细胞百分比及MCP-1基因表达,两者均降低Col1a1和Sparc表达并保留第14天滤过泡高度,MCP-Ri对小鼠Tenon囊成纤维细胞毒性低于MMC。作者认为靶向MCP-1可延长滤过泡存活且细胞毒性更小,可能为GFS中传统抗纤维化辅助治疗提供更安全的替代选择。

要点

  • MCP-Ri较MMC或对照更降低结膜滤过泡F4/80阳性细胞百分比和MCP-1基因表达。
  • MMC和MCP-Ri均降低Col1a1和Sparc表达但不降低纤连蛋白,两者均保留第14天滤过泡高度。
  • MCP-Ri对小鼠Tenon囊成纤维细胞毒性低于MMC。

核心结论

  • 靶向MCP-1可延长实验性GFS后滤过泡存活,且细胞毒性低于MMC。
  • 作者认为MCP抑制可能为GFS中传统抗纤维化辅助治疗提供更安全的替代选择。

研究设计与样本

  • 在C57/Bl6小鼠一只眼上行GFS(n=36),术中分别给予MCP-Ri、MMC或溶媒。
  • 术后第2天和第7天用实时聚合酶链反应评估结膜MCP-1、TGFB1、TGFB2、Col1a1、Sparc和纤连蛋白表达。
  • 术后第14天在体行前节裂隙灯检查、光学相干断层扫描和共聚焦显微镜检查。
  • 术后第2天行F4/80(单核-巨噬细胞标志物)免疫组化染色。
  • 体外实验比较MMC、MCP-Ri和溶媒对小鼠Tenon囊成纤维细胞活力的影响。

主要发现

  • MCP-Ri治疗较MMC或对照更降低结膜滤过泡中F4/80阳性细胞百分比,且MCP-1基因表达更低。
  • MMC和MCP-Ri均降低Col1a1和Sparc表达,但均不降低纤连蛋白。
  • TGFB1在MCP-Ri组降低而在MMC组不降低;TGFB2在MMC组降低而在MCP-Ri组不降低。
  • 与对照相比,MMC和MCP-Ri治疗均保留第14天滤过泡高度。
  • 与MMC相比,MCP-Ri对小鼠Tenon囊成纤维细胞毒性更低。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of treatment with monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) to maintain bleb survival and prevent fibrosis in an experimental model of glaucoma filtration surgery (GFS). METHODS: GFS was performed on one eye of C57/Bl6 mice (n = 36) that was treated with MCP-Ri, mitomycin-C (MMC), or vehicle at the time of surgery. Real-time polymerase chain reaction was used to evaluate conjunctival expression of monocyte chemoattractant protein-1 (MCP-1), TGFB1, TGFB2, collagen 1a1 (Col1a1), sparc (Sparc), and fibronectin at 2 and 7 days following surgery. Anterior segment slit-lamp examination, optical coherence tomography, and confocal microscopy were performed in vivo at day 14. Eyes were processed for immunohistochemical staining of F4/80, a monocyte-macrophage marker, at day 2. In vitro experiments were also performed to compare the effect of MMC, MCP-Ri, and vehicle on the viability of mouse Tenon's fibroblasts. RESULTS: Treatment with MCP-Ri results in a greater reduction in the percentage of F4/80-positive cells in conjunctival blebs and lesser MCP-1 gene expression following experimental GFS than MMC or control. Both MMC and MCP-Ri reduced Col1a1 and Sparc expression, but not fibronectin. TGFB1 decreased with MCP-Ri but not MMC; MMC but not MCP-Ri reduced TGFB2. MMC and MCP-Ri treatment resulted in the preservation of bleb height at day 14, as compared to control. MCP-Ri was less toxic to mouse Tenon's fibroblasts in comparison with MMC. CONCLUSIONS: Targeting MCP-1 results in prolonged bleb survival following experimental GFS with less cellular toxicity as compared to MMC. MCP inhibition could provide a safer alternative to conventional antifibrotic adjunctive treatments in GFS.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Chong RS, Lee YS, Chu SWL, et al. Inhibition of Monocyte Chemoattractant Protein 1 Prevents Conjunctival Fibrosis in an Experimental Model of Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci. 2017. PMID: 28692738. doi:10.1167/iovs.17-21480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。